Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells.
暂无分享,去创建一个
J. Jankovic | D. Rowe | S. Appel | W. Xie | W. Le | Dominic B. Rowe | Joseph Jankovic | Weidong Le | Stanley H. Appel
[1] M. Mattson,et al. Presence of 4‐hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis , 1998, Annals of neurology.
[2] S. Appel,et al. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. , 1998, Archives of neurology.
[3] W. D. Ehmann,et al. Elevated 4-Hydroxynonenal in Ventricular Fluid in Alzheimer’s Disease , 1997, Neurobiology of Aging.
[4] D. Wallach,et al. Cell death induction by TNF: a matter of self control. , 1997, Trends in biochemical sciences.
[5] G. Kreutzberg. Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.
[6] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[7] Peter Riederer,et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.
[8] L. Colom,et al. Cell death induced by β-amyloid 1–40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis , 1995, Brain Research.
[9] S. Appel,et al. Experimental autoimmune nigral damage in guinea pigs , 1995, Journal of Neuroimmunology.
[10] R. Norgren,et al. Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture , 1995, Neurology.
[11] E. Hirsch,et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.
[12] C. Marsden,et al. New insights into the cause of Parkinson's disease , 1992, Neurology.
[13] S. Ben‐Sasson,et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.
[14] J. Tajti,et al. Nigral damage and dopaminergic hypofunction in mesencephalon‐immunized guinea pigs , 1992, Annals of neurology.
[15] E. Stefani,et al. A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[16] C. Olanow. Oxidation reactions in Parkinson's disease , 1990, Neurology.
[17] Olanow Cw. Oxidation reactions in Parkinson's disease. , 1990 .
[18] C. Tanner,et al. The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.
[19] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[20] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[21] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[22] M. Naoi,et al. N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease. , 1997, Journal of neural transmission. Supplementum.
[23] P Riederer,et al. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.
[24] P. Riederer,et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. , 1994, Neuroscience letters.
[25] J. Bostwick,et al. A tyrosine hydroxylase assay in microwells using coupled nonenzymatic decarboxylation of dopa. , 1991, Analytical biochemistry.
[26] A. Dahlström,et al. Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. , 1990, Journal of neural transmission. Supplementum.